


CLAIMS

1. Use of a compound of formula (I):



wherein:

R₁ is H or methyl;

R₂ and R₃ are both methyl, or R₂ and R₃, together with the carbon atom to which they are attached, are a spirocyclopropyl ring;

R₄ is methyl or ethyl;

R₅ is H or methyl;

or R₄ and R₅, together with the carbon atom to which they are attached, form a C₃-C₄ spiro carbocyclyl;

or a pharmaceutically acceptable salt and/or solvate thereof,

in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder,

wherein the disease or disorder is selected from the group consisting of hearing disorders, schizophrenia, depression and mood disorders, bipolar disorder, substance abuse disorders, anxiety disorders, sleep disorders, hyperacusis and disturbances of loudness perception, Ménière's disease, disorders of balance, and disorders of the inner ear, impulse control disorder, personality disorders, attention-deficit/hyperactivity disorder, autism spectrum disorders, eating disorders, cognition impairment, ataxia, pain such as neuropathic pain, inflammatory pain and miscellaneous pain, Lewy body dementia and Parkinson's disease, or Fragile X syndrome,

wherein:


i) the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered at 2 to 400 mg per day; or

ii) wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered for a period of at least three months; or

iii) the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered orally at 1 to 500 mg per day once or twice per day; or

iv) the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered to a human subject aged 18 to 65.

2. The use according to claim 1 wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered at 2 to 400 mg per day.
3. The use according to claim 1, wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered for a period of at least three months.
4. The use according to claim 1, wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered orally at 1 to 500 mg per day once or twice per day.
5. The use according to claim 1, wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered to a human subject aged 18 to 65.
6. Use of a compound of formula (I):



wherein:

R₁ is H or methyl;

R₂ and R₃ are both methyl, or R₂ and R₃, together with the carbon atom to which they are attached, are a spirocyclopropyl ring;

R₄ is methyl or ethyl;

R₅ is H or methyl;

or R₄ and R₅, together with the carbon atom to which they are attached, form a C₃-C₄ spiro carbocyclyl;


or a pharmaceutically acceptable salt and/or solvate thereof,

in the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder, wherein the disease or disorder is selected from the group consisting of hearing disorders, schizophrenia, depression and mood disorders, bipolar disorder, substance abuse disorders, anxiety disorders, sleep disorders, hyperacusis and disturbances of loudness perception, Ménière's disease, disorders of balance, and disorders of the inner ear, impulse

control disorder, personality disorders, attention-deficit/hyperactivity disorder, autism spectrum disorders, eating disorders, cognition impairment, ataxia, pain such as neuropathic pain, inflammatory pain and miscellaneous pain, Lewy body dementia and Parkinson's disease, or Fragile X syndrome,

wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is to be administered to a human subject of less than 18 years of age.

7. The use according to any one of claims 1 to 6, wherein the compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof is a compound of formula (I):



wherein:

R₁ is H or methyl;

R₂ and R₃ are both methyl, or R₂ and R₃, together with the carbon atom to which they are attached, are a spirocyclopropyl ring;


R₄ is methyl or ethyl;

R₅ is H or methyl;

or R₄ and R₅, together with the carbon atom to which they are attached, form a C₃-C₄ spiro carbocyclyl;


or a pharmaceutically acceptable salt and/or solvate thereof.

8. The use according to any one of claims 1 to 7, wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is 5,5-dimethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxy pyrazin-2-yl]imidazolidine-2,4-dione:




9. The use according to any one of claims 1 to 7 wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is a pharmaceutically


acceptable salt of 5,5-dimethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione:




10. The use according to any one of claims 1 to 7 wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is (5R)-5-ethyl-3-(5-spiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione:




11. The use according to any one of claims 1 to 7 wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is a pharmaceutically acceptable salt of (5R)-5-ethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione:



12. The use according to any one of claims 1 to 7 wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is (5R)-3-[5-[(3,3-dimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]-5-ethyl-imidazolidine-2,4-dione:



13. The use according to any one of claims 1 to 7 wherein the compound of formula (I), or a pharmaceutically acceptable salt and/or solvate thereof is a pharmaceutically acceptable salt of (5R)-5-ethyl-3-(5-spiro[2H-benzofuran-3,1'-cyclopropane]-4-yloxy)pyrazin-2-yl)imidazolidine-2,4-dione:



14. The use according to any one of claims 1 to 13, wherein the disease or disorder is schizophrenia.
15. The use according to any one of claims 1 to 13, wherein the disease or disorder is a hearing disorder.
16. The use according to any one of claims 1 to 13, wherein the disease or disorder is pain.
17. The use according to claim 16, wherein the pain is neuropathic pain.